Product
Production volumes upon reaching full design capacity in 2031 will be as follows:
- Diagnostic test systems – 9,125 thousand doses.
Project
This investment project provides for the organization of production of medical test systems for laboratory diagnostics of infectious and parasitic human diseases in Almaty Oblast.
The Company plans to produce 31 types of test systems* to detect parasitic diseases (9 types), viral infections (8 types), bacterial infections (7 types) and sexually transmitted infections (7 types).
Currently, the Initiator has built a workshop building, with all required infrastructure in place.
Project Initiator
MVA Group Research and Production Center LLP is a research and production entity in the field of biotechnology, biosafety, immunology, and epidemiology. The Company’s specialists have developed and registered 5 test systems to diagnose infectious animal diseases.
Market overview
- According to a Technavio report, the global medical diagnostics market will grow at a steady pace during 2023-2027, at a CAGR of 6.2%. Market growth drivers include an increase in the elderly population, an increase in the incidence of chronic and infectious diseases, increased public awareness and increased government spending on healthcare.
- According to BusinesStat research, in 2021, the total cost of laboratory tests performed in Kazakhstan amounted to USD 786 million, which is 3.1 times more than in 2017. Market growth was due to an increase in population, centralization and automation of laboratory services, development of private services of laboratory diagnostics and expanding the range of tests.
- State support for the development of domestic production. Local production will ensure a stable and timely supply of medical test systems to the domestic market at competitive prices and allow reducing dependence on imports. As prescribed by the law, authorized government bodies are required to purchase medical drugs and products from local producers first, if any, and conclude long-term contracts with them. According to SK-Pharmacia's forecasts, domestic pharmaceutical manufacturers will reach about 50% in the Single Distributor's purchases in monetary terms by 2025, with the existing contracts taken into account.
- Experience of the Company's employees. The Initiator's team consists of qualified specialists with sound expertise in the development of manufacturing technologies and pilot industrial production of biological products for humans and animals.
The Project requires investment of 1,060 thousand USD (at the rate of 449.2 tenge), of which:
- 70% (742 thousand USD) - debt financing subject to collateral;
- 30% (318 thousand USD) – investor participation.
